Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Inhibikase Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 132.03 Mil.
Inhibikase Therapeutics's quarterly shares outstanding
increased
from Dec. 2025 (131.69 Mil) to Mar. 2026 (132.03 Mil).
It means Inhibikase Therapeuticsissued new shares from Dec. 2025 to Mar. 2026 .
Inhibikase Therapeutics's annual shares outstanding
increased
from Dec. 2024 (69.36 Mil) to Dec. 2025 (131.69 Mil).
It means Inhibikase Therapeuticsissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Inhibikase Therapeutics Shares Outstanding (EOP) Related Terms
Inhibikase Therapeutics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Inhibikase Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IKT vs FHTX, OBIO, FULC: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 132.03 Mil mean?
Inhibikase Therapeutics (IKT) has a Shares Outstanding (EOP) of 132.03 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Shares Outstanding (EOP) too high?
Inhibikase Therapeutics' current Shares Outstanding (EOP) is 132.03 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Shares Outstanding (EOP) compare to FHTX and OBIO?
Inhibikase Therapeutics' Shares Outstanding (EOP) of 132.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Shares Outstanding (EOP) is 132.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Shares Outstanding (EOP) of 132.03 Mil. The current Shares Outstanding (EOP) is 132.03 Mil. Inhibikase Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Shares Outstanding (EOP) is 132.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
34GF Score
Get the complete analysis for IKT
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
